Vanderbilt University Medical Center
Vanderbilt University Medical Center sponsors 677 registered US clinical trials on ClinicalTrials.gov, 130 of them currently recruiting, and 400 completed. 70 of these trials are in Phase 3-4 (later-stage) and 127 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autonomic Failure, with 9 trials.
Trial Pipeline
677 total, page 14 of 14
Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer
NCT00675636
Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes
NCT00399880
Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease
NCT00388453
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
NCT00378898
The Use of Colloid Versus Crystalloid in Post-operative Pediatric Cardiac Patients for Fluid Resuscitation
NCT00464126
Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI)
NCT00360022
DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx
NCT00897988
The Activity Intervention for Chemobrain
NCT00495703
Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C
NCT00525083
Study of Proteins in Head and Neck Cancer Cells
NCT00896948
Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers
NCT00899769
The Role of the Omentum in the Treatment of Morbid Obesity
NCT00212160
Use of Insulin Glargine to Treat Diabetic Ketoacidosis
NCT00179127
Elevated Serum HDL in Four Generations of a Nashville Family
NCT00525109
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer
NCT00482872
Risk Factors for Adult-Onset Brain Tumors
NCT00592865
AMP as a Better Delivery System of Adenosine
NCT00179010
Biochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubarche
NCT00581490
Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry
NCT00592709
Safety of Non-delayed Weight Bearing After Total Hip Replacement With Non-Cemented Fiber Metal Taper Stem
NCT00179088
Dynamic Measures of Neurochemistry in Mood Disorders
NCT00178828
Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants
NCT00899028
Biomagnetic Characterization of Gastric Dysrhythmias:Study 2
NCT00178984
Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
NCT00223678
Biomagnetic Signals of Intestinal Ischemia II
NCT00179036
The Pathophysiology of Orthostatic Hypotension
NCT00748059
Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography
NCT03910114
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 65 |
| Phase 2 | 62 |
| Phase 3 | 14 |
| Phase 4 | 56 |
Therapeutic Areas
What the Pipeline for Vanderbilt University Medical Center Shows
According to the ClinicalTrials.gov registry, Vanderbilt University Medical Center is linked to 677 US clinical trials across every stage of research activity. Of those, 130 studies are currently recruiting, about 19% of the sponsor's indexed portfolio, and 400 are already marked complete, representing roughly 59% of the total.
The phase mix for Vanderbilt University Medical Center reports 70 late-stage studies (Phase 3 and Phase 4 combined) and 127 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Vanderbilt University Medical Center is Autonomic Failure with 9 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.